Zydus Lifesciences Limited
Preview the depth — unlock the full forensic study.
You're reading the free Overview. The full Landscape study, the Lenses, governance and quality scans unlock with Pro — across 5,000 Indian companies.
Briefing
Zydus Lifesciences Limited — the brief
Forensic posture: Clean disclosures. Deloitte's audit comes back clean, but Zydus Life's filings reveal ₹11,427 Cr in unquantified contingent acquisition payables and a ₹67 Cr concentrated stake in a Sterling Biotech joint venture—material commitments that sit outside the usual earnings narrative.
Auditor’s report (CARO 2020)
Auditor’s assessment Clean. Auditor: Deloitte Haskins & Sells LLP. Fiscal year FY24-25.
Related-party transactions
Assessment Notable. Disclosed volume of ₹4 Cr across 33 related parties. Fiscal year FY24-25.
- Material contingent liabilities on acquisitions: Large contingent consideration payable of ₹11,427 Million for business acquisitions (Naturell, LiqMeds) creates significant unquantified obligations subject to milestone achievement.
- Major equity investment in Sterling Biotech JV: Substantial investment of ₹67.08 Cr in Sterling Biotech (50% JV) for gelatine/API business represents concentrated exposure to joint venture partner performance.
- Naturell acquisition with deferred consideration: Naturell acquisition involved ₹36.90 Cr upfront but ₹2.10 Cr deferred contingent consideration subject to FY2024-25 milestone achievement.
Contingent liabilities
Assessment Clean. Fiscal year FY25.
Corporate governance
Board of 9 directors, 56% independent. Chair: Mr. Pankaj R. Patel. Chair and CEO roles are separated. Statutory auditor: Deloitte Haskins & Sells LLP. Board remuneration: 0.0% of net profit. Fiscal year FY24-25.
“Financial liability related to contingent consideration [Refer Note-53 A and B] - 11,427 Million”
What retail misses·The contingent acquisition payables (₹11.4 Bn) and the ₹67 Cr Sterling Biotech JV stake appear in RPT and acquisition footnotes but are invisible to headline earnings; neither shows in news reports and both represent unquantified future cash outflows.
Strengths noted in disclosures: Auditor flagged zero high or material issues; audit opinion is clean. · Altman bankruptcy predictor scores 4.46 (safe zone) — low distress risk from leverage and profitability. · Earnings quality composite at 80 (excellent) with low manipulation risk and cash flow matching reported profit.
Forensic signal
From the company's own filingsStrong: Momentum · 52-Week · Size · Weak: Yield